Company
Official Name: Bristol-Myers Squibb Company
Headquarters: New York, NY, United States
Founded: 1887
Employees: 32,200
CEO: Dr. Giovanni Caforio M.D.
$108.83 Billion
USD as of Jan. 1, 2026
Bristol Myers Squibb Company, also known as BMS, is a multinational pharmaceutical company. Tracing its origins to1858, it develops and manufactures prescription pharmaceuticals and biologics for a diverse range of diseases including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| AstraZeneca | $284.38 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $48.03 B |
| EBITDA | $18.30 B |
| Gross Profit TTM | $35.14 B |
| Profit Margin | 12.57% |
| Operating Margin | 31.57% |
| Quarterly Revenue Growth | 2.80% |
Bristol-Myers Squibb Company has the following listings and related stock indices.
Stock: NYSE: BMY wb_incandescent
Stock: FSX: BRM wb_incandescent
Stock: XETR: BRM wb_incandescent
Founder(s): William Mc Laren Bristol John Ripley Myers E. R. Squibb
Giovanni Caforio, M. D. (Chairman & CEO) David Elkins (CFO)